DAN-222 + niraparib

DAN-222 + niraparib is an investigational combination therapy for cancer that pairs a novel high-capacity drug conjugate (DAN-222) with the PARP inhibitor niraparib. DAN-222 is a polymeric nanoparticle-based drug conjugate delivering a topoisomerase I inhibitor payload. Niraparib is an oral small molecule PARP inhibitor approved for maintenance treatment in ovarian and other cancers. The combination leverages the DNA-damaging effects of topoisomerase I inhibition with impaired DNA repair from PARP inhibition, resulting in synergistic antitumor activity demonstrated in preclinical models and early clinical trials—particularly in HER2-negative metastatic breast cancer and both HRD+ and HRD– tumor types[1][5][7]. Early-phase studies show promising efficacy (notably higher rates of stable disease compared to monotherapy), good tolerability, and reduced myelotoxicity relative to other regimens[2][4][5].

Brand names

Zejula

Other names

DAN 222DAN222DAN-222Zejula + DAN-222